ADVISORY/Photo of Jeff Cornish at Amgen's new facility in Longmont Colorado is available on BW PhotoWire/AP PhotoExpress, NewsCom, PressLink and Business Wire's Web Site.Photo/Business ADVISORY... --(BUSINESS WIRE) The photo is BW2 on AP PhotoExpress. The photo is on Business Wire's Web Site at URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. : http://www.businesswire.com/cgi-bin/photo.cgi?pw.070600/bw2 Photo caption reads: Jeff Cornish, an Amgen manufacturing associate, examines a roller bottle container holding cell cultures in the warm room of Amgen's new facility in Longmont Colorado on Saturday, July 1, 2000. The Food and Drug Administration has licensed the 450,000 square foot facility to manufacture the breakthrough anemia drug Epoetin alfa e·po·e·tin al·fa n. A recombinant preparation of human erythropoietin used to treat some forms of anemia. epoetin alfa Epogen, Eprex (CA) (UK), Procrit Pharmacologic class: . The new plant will ultimately have three times more production capacity for Epoetin alfa than the company's existing facility. Amgen also expects to manufacture its new anemia drug, Novel Erythropoiesis erythropoiesis /eryth·ro·poi·e·sis/ (-poi-e´sis) the formation of erythrocytes.erythropoiet´ic e·ryth·ro·poi·e·sis n. The formation or production of red blood cells. Stimulating Protein (NESP NESP Neuroendocrine Secretory Protein NESP Navy EHF SATCOM Program NESP Nurse Educator Scholarship Program NESP Navy EHF Satellite Program NESP National Environmental Studies Project NESP National Education Supercomputer Program ), currently under FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review, at the Longmont plant. (V. Richard Haro/WirePix) (Business Wire photo) See BW238 (CA-AMGEN) that ran earlier today for more information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion